VOLITIONRX LTD
VNRXNYSE AMERICANTrading Snapshot
- Day Range
- $0.25 – $0.26
- 52-Week Range
- $0.23 – $14.80
- Volume
- $4.89B
- Avg Volume
- $4.08B
- Shares Outstanding
- 8.3M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $398,657
- P/E Ratio
- -0.1
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-2.80
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +23.5%
Why Investors Own VNRX
- ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VOLITIONRX LTD
VNRX
StockOtter · stockotter.spaceAbout VOLITIONRX LTD
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX ) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETEC
VolitionRx Participates in Launch of DETECSEPS Program in France
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev., Sept. 17, 2026 /PRN
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the out
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
VolitionRX (NYSEAMERICAN:VNRX) Share Price Crosses Below Fifty Day Moving Average – Here’s Why
Shares of VolitionRX Limited (NYSEAMERICAN:VNRX - Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.87 and traded as low as $0.3362. Volition
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and comm